Across TCGA pan-cancer cohorts, ZNF859P RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated ZNF859P data layer.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ZNF859P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF859P expression acts as an unfavorable survival marker, although some lineages such as HNSC and PAAD show a favorable association.
CESC, LIHC, and BRCA are the cancer types where ZNF859P RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.